Local Study of Akatinol Memantine in VaD in Russia
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The study evaluates the clinical efficacy and safety of Akatinol Memantine 20 mg
(single-doses) vs. Akatinol Memantine 10 mg (double-doses) in patients suffering from
moderate and moderately severe vascular dementia.